NWRN.SW

Newron Pharmaceuticals S.p.A. [NWRN.SW] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

NWRN.SW Stock Summary

Top 10 Correlated ETFs

NWRN.SW

Top 10 Correlated Stocks

NWRN.SW

In the News

NWRN.SW Financial details

Company Rating
-
Market Cap
143.28M
Income
-30.28M
Revenue
14.68M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
22
Optionable
No
Shortable
Yes
Earnings
14 Mar 2024
P/E
-8.49
Forward P/E
-
PEG
-1.16
P/S
24.36
P/B
-10.58
P/C
-
P/FCF
-13.36
Quick Ratio
4.52
Current Ratio
5.65
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.7
EPS next Y
-
EPS next Q
-
EPS this Y
-7.14%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-4.24%
Revenue last 5Y
5.17%
Revenue Q/Q
68.32%
EPS Q/Q
-22%
-
-
-
-
SMA20
25.82%
SMA50
-17.11%
SMA100
1.89%
Inst Own
-
Inst Trans
-
ROA
-47%
ROE
320%
ROC
-0.41%
Gross Margin
100%
Oper. Margin
-218%
Profit Margin
-287%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
3.7-10.8
52W High
-21.4%
52W Low
+162%
RSI
52.89
Rel Volume
0.26
Avg Volume
105.13K
Volume
27.78K
Perf Week
-1.01%
Perf Month
4.11%
Perf Quarter
11.81%
Perf Half Y
5.5%
-
-
-
-
Beta
0.703
-
-
Volatility
0.12%, 0.74%
Prev Close
-2.12%
Price
7.86
Change
-6.43%

Something similar

Top by Market Cap
BRYN.DE
FXAIX
LLY.DE
DHR-PB
AVGO
Top Correlated ETFs
SYBM.DE
ESP0.DE
IUSP.DE
SPFA.DE
WTDX.DE
Top Correlated Stocks
NP5.DE
EVS.BR
A7A.DE
AIXA.DE
0N9Z.L
Similar Market Cap
AUGM.L
FXY
LLQ.SW
EMYB
MZX.DE

Company Profile

Healthcare Biotechnology
  • Volume Average 105.13K
  • Market Capitalization 143.28M
  • Employee 22
  • CEO Mr. Stefan Weber
  • Headquarters Bresso,MI,IT
  • IPO Date 2006-12-12
  • Website https://www.newron.com

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.